Edition:
United Kingdom

Calyxt Inc (CLXT.OQ)

CLXT.OQ on NASDAQ Stock Exchange Global Market

13.58USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$13.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,884
52-wk High
$22.32
52-wk Low
$8.83

Summary

Name Age Since Current Position

Andre Choulika

54 2010 Chairman of the Board

James Blome

56 2018 Chief Executive Officer, Director

William Koschak

49 2019 Chief Financial Officer

Daniel Voytas

56 2010 Chief Scientific Officer

Debra Frimerman

39 2019 General Counsel

Manoj Sahoo

42 2017 Chief Commercial Officer

Philippe Dumont

67 2017 Independent Director

Jonathan Fassberg

53 2018 Independent Director

Anna Kozicz-Stankiewicz

44 2017 Independent Director

Kimberly Nelson

52 2019 Independent Director

Christopher Neugent

58 2018 Independent Director

Yves Ribeill

59 2018 Independent Director

Biographies

Name Description

Andre Choulika

Dr. Andre Choulika, Ph.D., is Chairman of the Board of the company since August 2010Dr. Choulika is one of the founders of Cellectis, and has served as Chief Executive Officer of Cellectis since the company’s inception in 1999. He has served as the Chairman of the Board of Directors of Cellectis since 2011. Since December 2014, Dr. Choulika has served as Chief Executive Officer of Cellectis, Inc. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from HEC (Challenge +). Based on Dr. Choulika’s deep knowledge of our company and scientific experience, we believe Dr. Choulika has the appropriate set of skills to serve as a member of our Board of Directors.

James Blome

Mr. James A. Blome is Chief Executive Officer, Director of the Company. Jim Blome grew up on a family corn and soybean farm in Hubbard, Iowa and a graduate of Iowa State University. Prior to joining Calyxt, Jim was the President and CEO for Bayer CropScience LP (North America). He held executive positions at Valent (Sumitomo Chemical) and Agriliance LLC before joining Bayer. Jim serves as the Chairman of CropLife America, Chairman of US Farming and Ranching Foundation, the Independent, Non-Executive Chairman of Concentric Ag Technologies, Inc. Jim is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture. Kincannon & Reed, a leading executive search firm focused on the food, agribusiness, and biosciences sectors, assisted Calyxt

William Koschak

Mr. William F. Koschak has been appointed as Chief Financial Officer of the company effective as of January 7, 2019. He previously served as the Vice President, Finance of the Brain Therapies division of Medtronic plc, a global medical technology company, from June 2017 through January 2019. During this time, Mr. Koschak also served as interim Vice President and General Manager, Brain Modulation at Medtronic plc from May 2018 through October 2018. Prior to joining Medtronic plc, Mr. Koschak served as the Executive Vice President and Chief Financial Officer of Young America Holdings, LLC, a privately held digital services firm, beginning in December 2014. Earlier in his career, Mr. Koschak held various finance positions at General Mills, where he was employed from May 2005 until December 2014. Prior to General Mills, Mr. Koschak was an audit partner at KPMG LLP. Mr. Koschak has a Bachelor of Arts degree from Augsburg College.

Daniel Voytas

Prof. Daniel F. Voytas, Ph.D., is Chief Science Officer of the company since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our co-founders and one of the inventors of the TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota (UMN), which he joined in 2008, and Director of the UMN’s Center for Genome Engineering. In 1992, Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science.

Debra Frimerman

Ms. Debra H. Frimerman has been appointed General Counsel of the Company effective February 11, 2019. Before joining Calyxt, Ms. Frimerman was Associate General Counsel for Syngenta North America, as well as acting General Counsel for Syngenta Seeds, LLC. Through her seven years at Syngenta, she provided counsel for executive leadership teams and contributed to the closing of numerous global transactions; launching new products into new markets; and developing regulatory, compliance and corporate policies. Prior to her role at Syngenta, Ms. Frimerman practiced law at Stoel Rives LLP and Lindquist & Vennum PLLP (now Ballard Spahr).

Manoj Sahoo

Mr. Manoj Sahoo is Chief Commercial Officer of the company since March 2017. He holds a MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemical Engineering from the National Institute of Technology in India. Mr. Sahoo has more than two decades of experience working in a variety of roles covering commercial, strategy, business development and mergers and acquisitions for global corporations in agriculture, food, energy and materials fields. Prior to joining us he was Assistant Vice President for Food Ingredients and Bio-industrial Enterprise at Cargill. At Cargill, he was responsible for revenues of over $1 billion, leading the commercial enterprise team to triple its earnings from bio-based products and managing relationships with large institutional customers. His prior roles at Cargill included Business Development Director for Starches and Sweeteners North America as well as serving as an investment team member with the Emerging Business Accelerator, a group structured along corporate venture capital groups, to invest in white space opportunities for Cargill; he also worked in the Corporate Strategy & Development Group. Mr. Sahoo has also served on the boards of both Calysta Inc. and Rivertop Renewables as a Cargill representative. He was responsible for leading Cargill’s equity investments in the industrial biotechnology space including co-investment in real assets with institutional financial investors to build a $600 million commercial-scale aquaculture nutrition plant. He also serves on Industry Advisory Board of Larta Institute which assists the USDA, NIH and NSF with the commercialization assistance program.

Philippe Dumont

Mr. Philippe Dumont is Independent Director of the company since July 2017. Mr. Dumont retired in December 2012 from Bayer CropScience, where he was employed since May 2002. At Bayer he held the position of Head of Technology Management, Seeds, and was responsible for supervising globally the Regulatory Affairs and Regulatory Science functions, Stewardship, Public and Governmental Affairs and Communication impacting GMOs and seeds. Until 2006 Mr. Dumont also supervised the Legal and Intellectual Property functions in the seed business. Mr. Dumont also held the same responsibilities at Aventis Crop Science from December 1998 until April 2002. From 1987 to 1998, Mr. Dumont was General Counsel of Rhône-Poulenc Agrochimie. Prior to moving to France in 1987, Philippe held positions as an associate at Cravath Swaine & Moore (1975 – 1981), international legal counsel at Gulf Oil Corporation (1981-1983) and as solo practitioner in Washington D.C. from 1983 – 1986. Philippe is retired from the New York and District of Columbia Bars and is a graduate of the Georgetown University Law Center (JD 1975) and Columbia University (BA, magna cum laude 1972). Since June 2013 he has been serving as a director of Association Française des Biotechnologies Végétales, responsible for international relations, where he tries to promote public and governmental understanding of new breeding techniques and related regulatory issues. Based on his leadership and regulatory experience in the plant biotechnology industry, we believe Mr. Dumont has the appropriate set of skills to serve as a member of our Board of Directors.

Jonathan Fassberg

Mr. Jonathan B. Fassberg is Independent Director of the Company. He is founder of the Trout Group and currently Co-Chief Executive Officer of Solebury Trout. He is member of the Audit Committee. Mr. Fassberg founded The Trout Group in 1996 and has been the Co-Chief Executive Officer of Solebury Trout LLC since the Trout Group’s acquisition by Solebury Communications in 2017. Mr. Fassberg holds a Bachelor of Science degree in biology and chemistry from The University of North Carolina – Chapel Hill and a Master of Business Administration degree in finance from New York University’s Stern School of Business. Based on his deep financial expertise and experience, we believe Mr. Fassberg has the appropriate set of skills to serve as a member of our Board.

Anna Kozicz-Stankiewicz

Ms. Anna Ewa Kozicz-Stankiewicz is Independent Director of the company since July 2017. Mrs. Kozicz received a BA in Math and Economics from Columbia College and her MBA from Columbia Business School. She started her career in 1996 at Credit Suisse First Boston in its Financial Institutions Group before moving to Goldman Sachs in 2000 where she held multiple positions, including Managing Director, and spent most of her time in the Principal Strategies Group with a focus on the global agricultural sector. She moved to Caxton Associates in 2009 to work as an equity Portfolio Manager before moving to BlackRock in 2012 where she worked as Head of US Strategy and Corporate Development as well as a private assets Portfolio Manager. During her time at BlackRock, she served as a director on the board of a New York-based federal credit union (PSFCU). She left BlackRock in 2017 to start a new investment platform, Anthelion Capital, focused on sustainability in agriculture, energy and transportation services.

Kimberly Nelson

Ms. Kimberly K. Nelson is Independent Director of the Company. Kim Nelson is the Executive Vice President and Chief Financial Officer at SPS Commerce, providing financial direction at a number of companies over her 30 years of experience including Amazon.com, Nestlé USA Inc. and The Pillsbury Company. In her current role, Kim has led SPS Commerce to a successful IPO, navigated their company's growth through creation of their M&A program and continues to oversee their financial systems, controls and models to ensure their financial position is flourishing. In addition to her new position as a Director on Calyxt's board, she also advises on the Board of Directors for Qumu. Prior to this position, Mrs. Nelson was the Finance Director for Amazon.com in a number of their practice areas such as Corporate Planning and Analysis, Investor Relations and Technology.

Christopher Neugent

Mr. Christopher J. Neugent serves as Independent Director of the Company. Mr. Neugent, has served as the Executive Vice President of Strategy of Post Holdings, Inc. since July 2018. Prior thereto, he served as President and CEO, Post Consumer Brands, from November 2015 until July 2018. Previously, Mr. Neugent served as the President and Chief Executive Officer of MOM Brands Company since May 2015, when Post acquired MOM Brands Company. From 2001 until the acquisition, Mr. Neugent served in various roles at MOM Brands Company, most recently as Chairman and CEO. Mr. Neugent has served on the Board of Directors of Welch Foods Inc. since February 2016. He holds a Bachelor of Arts degree in economics from Princeton University and completed the Advanced Management Program at the Wharton School of Business. Mr. Neugent has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors.

Yves Ribeill

Dr. Yves Joseph Ribeill, Ph.D. Independent Director is of the Company. He founded SCYNEXIS, Inc (NASDAQ: SCYX) and served as President and CEO from 1999 to 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases including bacterial, fungal, viral and parasiticidal and in microbiome-centric diseases. Prior to moving to the U.S. 21 years ago, Dr. Ribeill held several management positions during his international career with Rhône-Poulenc and Aventis in France and in the UK. Dr. Ribeill was a member of the Scientific Advisory Committee of the World Health Organization, the Medicines for Malaria Venture and is currently Vice Chairman of the Triangle Global Health Consortium in North Carolina.

Basic Compensation